Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Has Consensus Target Price of $7.50

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $7.50.

A number of equities analysts have recently weighed in on ZNTL shares. Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, September 30th. They set an “equal weight” rating and a $5.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Friday, October 2nd. Leerink Partners assumed coverage on Zentalis Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $8.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, October 19th. Finally, William Blair started coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They set an “outperform” rating for the company.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $1.96 on Friday. The company has a market capitalization of $140.47 million, a PE ratio of -1.01 and a beta of 1.91. The firm has a 50 day moving average price of $2.95 and a two-hundred day moving average price of $3.45. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). As a group, research analysts expect that Zentalis Pharmaceuticals will post -2.11 EPS for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters acquired 4,335,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the transaction, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This represents a 32.09% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $18,205,000. Seven Fleet Capital Management LP lifted its stake in Zentalis Pharmaceuticals by 188.7% during the second quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock worth $1,451,000 after purchasing an additional 207,600 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Zentalis Pharmaceuticals in the second quarter worth $1,815,000. Primecap Management Co. CA bought a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $4,643,000. Finally, Bank of America Corp DE bought a new position in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $5,406,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.